Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage

dc.contributor.authorGe CR
dc.contributor.authorTong DM
dc.contributor.authorLiang BB
dc.contributor.authorLonnblom E
dc.contributor.authorSchneider N
dc.contributor.authorHagert C
dc.contributor.authorViljanen J
dc.contributor.authorAyoglu B
dc.contributor.authorStawikowska R
dc.contributor.authorNilsson P
dc.contributor.authorFields GB
dc.contributor.authorSkogh T
dc.contributor.authorKastbom A
dc.contributor.authorKihlberg J
dc.contributor.authorBurkhardt H
dc.contributor.authorDobritzsch D
dc.contributor.authorHolmdahl R
dc.contributor.authorHolmdahl R
dc.contributor.organizationfi=MediCity|en=MediCity|
dc.contributor.organization-code2607003
dc.converis.publication-id26036558
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/26036558
dc.date.accessioned2022-10-28T13:12:57Z
dc.date.available2022-10-28T13:12:57Z
dc.description.abstractToday, it is known that autoimmune diseases start a long time before clinical symptoms appear. Anti-citrullinated protein antibodies (ACPAs) appear many years before the clinical onset of rheumatoid arthritis (RA). However, it is still unclear if and how ACPAs are arthritogenic. To better understand the molecular basis of pathogenicity of ACPAs, we investigated autoantibodies reactive against the C1 epitope of collagen type II (CII) and its citrullinated variants. We found that these antibodies are commonly occurring in RA. A mAb (ACC1) against citrullinated C1 was found to cross-react with several noncitrullinated epitopes on native CII, causing proteoglycan depletion of cartilage and severe arthritis in mice. Structural studies by X-ray crystallography showed that such recognition is governed by a shared structural motif "RG-TG" within all the epitopes, including electrostatic potential-controlled citrulline specificity. Overall, we have demonstrated a molecular mechanism that explains how ACPAs trigger arthritis.
dc.identifier.jour-issn2379-3708
dc.identifier.olddbid180538
dc.identifier.oldhandle10024/163632
dc.identifier.urihttps://www.utupub.fi/handle/11111/31304
dc.identifier.urnURN:NBN:fi-fe2021042717075
dc.language.isoen
dc.okm.affiliatedauthorHolmdahl, Rikard
dc.okm.affiliatedauthorHagert, Cecilia
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherAMER SOC CLINICAL INVESTIGATION INC
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumberARTN e93688
dc.relation.doi10.1172/jci.insight.93688
dc.relation.ispartofjournalJCI Insight
dc.relation.issue13
dc.relation.volume2
dc.source.identifierhttps://www.utupub.fi/handle/10024/163632
dc.titleAnti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage
dc.year.issued2017

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
JCI Insight93688.pdf
Size:
4.22 MB
Format:
Adobe Portable Document Format
Description:
Publisher's version